Possible scenario
Fast Launch Uptake
40% Chance
Juvmo becomes a major commercial addition to AbbVie's neuroscience portfolio after FDA approval, helped by once-daily dosing and strong phase 3 data inherited from Cerevel. Neurologists adopt it as a convenient option for Parkinson's patients needing better motor-symptom control.
Secondary impacts
- Healthcare +0.4%
Tickers
- ABBV+6.3%
- AMRX-1.7%
- SUPN-1.1%
Portfolio impact
S&P 500+0.1%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.